🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Breast Cancer Recurrent

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a1 site📍 Sioux Falls Sanford Health PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients NCT05440227Phase 21 site📍 Taipei PhytoHealth Corporation · Tests: PG2 Lyo. Injection 500mg, Placebo 0.9% normal saline A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites📍 Los Angeles📍 Los Angeles📍 Whittier Daiichi Sankyo · Tests: Ifinatamab deruxtecan 18F-FDG PET/CT Imaging for Breast Cancer NCT05730608NA1 site📍 Drammen Vestre Viken Hospital Trust · Tests: 18F-FDG PET/CT Breast Cancer Proteomics and Molecular Heterogeneity NCT01840293n/a6 sites📍 Cork📍 Dublin📍 Dublin Cancer Trials Ireland Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites📍 Gilbert📍 Beverly Hills📍 Duarte Relay Therapeutics, Inc. · Tests: Zovegalisib, Capivasertib, Fulvestrant PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer NCT02732171NA1 site📍 Philadelphia Abramson Cancer Center at Penn Medicine · Tests: Research Blood Collection A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks NCT07469709n/a1 site📍 Candiolo Fondazione del Piemonte per l'Oncologia A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer NCT04521764Phase 11 site📍 Rochester Mayo Clinic · Tests: Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein, Computed Tomography, Magnetic Reson… Prospective Assessment of Quality of Life in Patients With Locally Recurrent Breast Cancer and Hyperthermic Radiotherapy NCT04878666n/a1 site📍 Tübingen University Hospital Tuebingen Partial Breast Re-irradiation in Women in Women with Locally Recurrent Breast Cancer Previously Treated with Conservative Surgery and Whole Breast Irradiation NCT05772390Phase 21 site📍 Meldola Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IR… · Tests: Partial breast re-irradiation Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene NCT06817694NA1 site📍 Québec CHU de Quebec-Universite Laval · Tests: Cognitive-behavioral group therapy ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer NCT07173751Phase 3224 sites📍 Springdale📍 La Jolla📍 Los Alamitos BioNTech SE · Tests: Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine, Carboplatin, Eribulin Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior NCT01000883n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, laboratory biomarker analysis, biopsy QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC NCT06786026Phase 21 site📍 Shanghai Fudan University · Tests: bevacizumab, QL1706, Nab paclitaxel NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) NCT06081244Phase 343 sites📍 Baden-Baden📍 Böblingen📍 Freiburg im Breisgau Women's Cancer Study Group GmbH · Tests: Sacituzumab govitecan, Pembrolizumab A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) NCT07208149Phase 1, Phase 21 site📍 Beijing Shenzhen Majory Biotechnology Co., Ltd. · Tests: MR001 Bispecific Antibody for Injection Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer NCT07558733Phase 1, Phase 27 sites📍 Los Angeles📍 Lone Tree📍 Springfield Faeth Therapeutics · Tests: Serabelisib, Sapanisertib, Fulvestrant An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. NCT07357597Phase 441 sites📍 Tucson📍 Hot Springs📍 Little Rock AstraZeneca · Tests: Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd) Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC NCT05464082Phase 21 site📍 Salt Lake City University of Utah · Tests: Functional Precision Oncology A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC. NCT06371274NA1 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: ATRA, Toripalimab Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer NCT06217874n/a1 site📍 Rochester Mayo Clinic · Tests: Non-Interventional Study FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy NCT06185569n/a5 sites📍 Besançon📍 Bordeaux📍 Bordeaux Centre Hospitalier Universitaire de Besancon Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer NCT06900647Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Bortezomib (B), Cisplatin (CDDP), Bortezomib (B), Bortezomib (B), Cisplatin (CDDP) A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer NCT06957886Phase 32 sites📍 Guangzhou📍 Changsha Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M07D1, Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation NCT06952803Phase 3346 sites📍 Phoenix📍 Tucson📍 La Jolla AstraZeneca · Tests: Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT) A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors NCT06465069Phase 139 sites📍 Duarte📍 La Jolla📍 Los Angeles Eli Lilly and Company · Tests: LY4052031, Pembrolizumab Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer NCT06081959Phase 31 site📍 Beijing Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Tests: SKB264, Eribulin, Capecitabine, Gemcitabine, Vinorelbine Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) NCT04434040Phase 27 sites📍 San Francisco📍 Chicago📍 New Lenox Dana-Farber Cancer Institute · Tests: Atezolizumab, Sacituzumab govitecan
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy